Darryl Y. Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Darryl Y. Chan has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Aarushi Gupta
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
16 shared publications - Andreas Trumpp
German Cancer Research Center (DKFZ), Heidelberg, Germany
16 shared publications - Andy G. X. Zeng
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
16 shared publications - Caitlyn Vlasschaert
Queen's University
16 shared publications - Elisa Donato
German Cancer Research Center, Heidelberg, Germany
16 shared publications - Enrique Sanz-Garcia
Princess Margaret Cancer Centre 4 Toronto, Ontario
16 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eadz3612
Statins promote muscle metabolic danger and NLRP3-mediated myopathy via lower protein-prenylation and YAP
Statin intolerance and side effects such as low-level myopathy limit statin use and the dose for optimal cholesterol lowering. We found that priming the NLRP3 inflammasome with bacterial components like lipopolysaccharide lowered the dose of statins that caused side effects in muscle cells. We then built models of low-level statin myopathy and found that muscle cell–autonomous statin-induced myopathy occurs through the NLRP3 inflammasome in vitro and in mice. Statin-induced muscle cell death and higher Atrogin-1 were prevented by blocking NLRP3 or restoring isoprenoids but not cholesterol. Statins reduced glycolysis in muscle cells, which required lower protein prenylation. Statins lowered YAP effector genes and promoted nuclear accumulation of FOXO. Activating YAP, restoring isoprenoids, or blocking NLRP3 mitigated nuclear FOXO accumulation, statin-induced muscle atrophy, and statin-mediated lowering of protein synthesis. These results define a statin-induced myopathy pathway where metabolic danger engages the NLRP3 inflammasome and YAP via lower prenylation independent of cholesterol.
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eadz3612
Open AccessStatins promote muscle metabolic danger and NLRP3-mediated myopathy via lower protein-prenylation and YAP
Statin intolerance and side effects such as low-level myopathy limit statin use and the dose for optimal cholesterol lowering. We found that priming the NLRP3 inflammasome with bacterial components like lipopolysaccharide lowered the dose of statins that caused side effects in muscle cells. We then built models of low-level statin myopathy and found that muscle cell–autonomous statin-induced myopathy occurs through the NLRP3 inflammasome in vitro and in mice. Statin-induced muscle cell death and higher Atrogin-1 were prevented by blocking NLRP3 or restoring isoprenoids but not cholesterol. Statins reduced glycolysis in muscle cells, which required lower protein prenylation. Statins lowered YAP effector genes and promoted nuclear accumulation of FOXO. Activating YAP, restoring isoprenoids, or blocking NLRP3 mitigated nuclear FOXO accumulation, statin-induced muscle atrophy, and statin-mediated lowering of protein synthesis. These results define a statin-induced myopathy pathway where metabolic danger engages the NLRP3 inflammasome and YAP via lower prenylation independent of cholesterol.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het dendritic cells do not costimulate CD8 T cells more potently than their wild type counterparts
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
TET2-CH colorectal and melanoma cancer patients show enhanced immune infiltration
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of immunotherapy-treated melanoma patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
In isotype-control condition, Tet2het TILs are enriched for B cells, naïve CD4 and naïve CD8 T Cells, and MDSCs
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
CH mutational profile of NCT02644359 patients
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Mice with 20% Tet2-mutant hematopoiesis do not show an attenuation of tumor growth in immunotherapy response rate
- Open Access
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments
- 16 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation
Tet2het cells composed the majority of stem and progenitor cells in competitive transplantation experiments